Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma

Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision lo...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Callaghan, Jeffrey, Delaney, Conor, O’Connor, Merissa, van Batenburg-Sherwood, Joseph, Schicht, Martin, Lütjen-Drecoll, Elke, Hudson, Natalie, Ni Dhubhghaill, Sorcha, Humphries, Peter, Stanley, Chris, Keravala, Annahita, Chalberg, Thomas, Lawrence, Matthew S., Campbell, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115410/
https://www.ncbi.nlm.nih.gov/pubmed/37075118
http://dx.doi.org/10.1126/sciadv.adf6537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115410/
https://www.ncbi.nlm.nih.gov/pubmed/37075118
http://dx.doi.org/10.1126/sciadv.adf6537

Ejemplares similares